RAPT Therapeutics(RAPT) - 2023 Q4 - Annual Results
RAPT Therapeutics(RAPT)2024-03-07 13:03"We are working diligently to lift the clinical hold on our Phase 2 trials of zelnecirnon in atopic dermatitis and asthma," said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. "Patient safety is our top priority. We expect to provide an update once we have defined a plan to move ahead and appreciate your patience during this process. Separately, our Phase 2 study of tivumecirnon in cancer is ongoing and we will be presenting an update at AACR in April." Financial Result ...